| Next 10 |
Ad
AKBLF News and Press Alk-Abello A/S
home / stock / akblf / akblf news
-
U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents PR Newswire – ODACTRA is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons ...
-
ALK-Abelló A/S press release (OTCPK:AKBLF): Q1 GAAP EPS of $0.70. Revenue of $1.16B (+13.7% Y/Y). Outlook for 2022, ALK is maintaining its full-year outlook: Revenue is still expected to grow 8-12% in local currencies with tablet sales up by ~20%; EBITDA is still expected to increa...
-
ALK-Abelló A/S press release (OTCPK:AKBLF): Q4 EBITDA more than doubled to DKK136M vs. DKK64M, reflecting higher sales, improved gross margins and a modest increase in capacity costs. Revenue of DKK 1.1B (+11.0% Y/Y). For 2022, ALK expects revenue growth of 8-12% and a further impro...
-
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have ...
-
ALK-Abelló A/S (OTCPK:AKBLF): Q2 Operating profit was at DKK 48M Revenue of DKK 866M Press Release For further details see: ALK-Abelló A/S reports Q2 results
-
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - Acquisition Supports ALK's Commitment to Provide Innovative Solutions to Address the Needs of Healthcare Providers, Including ENTs, and their Patien...
-
U.S. FDA Approves ALK's RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis - RAGWITEK is now indicated to treat ragweed ...
-
ALK-Abelló A/S (AKBLF): Q3 GAAP EPS of DKK1.8Revenue of DKK772M (+4.4% Y/Y)Press Release For further details see: ALK-Abelló A/S reports Q3 results
-
Actress and Entrepreneur JoAnna Garcia Swisher and Husband, Former MLB World Champion Nick Swisher, Join New Campaign to Empower Allergy Sufferers to Take Control of Their Allergies - New survey results reveal 71 percent of U.S. adults have experienced environmental allergy symp...
-
ROUND ROCK, Texas , June 17, 2020 /PRNewswire/ -- ALK ( ALKB:DC / OMX:ALK B / AKABY / AKBLF ) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy...
Stock Information
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
Get AKBLF Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
